Pancreatic Safety of Sitagliptin in the TECOS Study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41262

Title:	Pancreatic Safety of Sitagliptin in the TECOS Study.
Authors:	Buse, John B Bethel, M Angelyn Green, Jennifer B Stevens, Susanna R Lokhnygina, Yuliya Aschner, Pablo Grado, Carlos Raffo Tankova, Tsvetalina Wainstein, Julio Josse, Robert Lachin, John M Engel, Samuel S Patel, Keyur Peterson, Eric D Holman, Rury R View more
Mesh:	Acute Disease Aged Cardiovascular Diseases Diabetes Mellitus, Type 2 Dipeptidyl-Peptidase IV Inhibitors Double-Blind Method Female Follow-Up Studies Humans Male Middle Aged Pancreatic Neoplasms Pancreatitis Proportional Hazards Models Risk Factors Sitagliptin Phosphate Treatment Outcome View more
Issue Date:	Feb-2017
Citation:	Diabetes Care.2017 Feb;(40)2:164-170
Abstract:	We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).
PMID:	27630212
URI:	https://hdl.handle.net/20.500.12530/41262
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > FIB H. U. Príncipe de Asturias > Artículos

Files in This Item:

File	Description	Size	Format
PMC5864139.pdf		1.01 MB	Adobe PDF	View/Open